Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suffers from a primary diagnosis of Generalized Anxiety Disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria.~* Has a Hamilton Anxiety Scale total score ≥20 at Screening and Baseline.~* Has a Hamilton Anxiety Scale score ≥2 on both Item 1 (anxious mood) and Item 2 (tension) at Screening and Baseline.~* Has a Montgomery-Åsberg Depression Rating Scale total score ≤16 at Screening and Baseline.~* Male and females of childbearing potential who are sexually active agree to use adequate contraception from Screening throughout the duration of the study and for 1 month after the last dose of study medication.~Exclusion Criteria:~* Has received any investigational compound \<30 days before Screening or 5 half-lives prior to Screening.~* Has received Lu AA21004 in a previous clinical study or as a therapeutic agent.~* Has 1 or more of the following:~  * Any current psychiatric disorder other than Generalized Anxiety Disorder as defined in the DSM-IV-TR.~ * Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.~ * Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR.~ * Presence or history of a clinically significant neurological disorder (including epilepsy).~ * Neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington disease, etc).~ * Any Axis II disorder that might compromise the study.~* Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study including:~  * Nonsteroidal anti-inflammatory drugs~ * Rifampin~ * Macrolide antibiotics~ * Hormones~ * Hypoglycemic agents and Insulin~ * Systemic steroids~ * Antineoplastics~ * Antiobesity agents~ * Antidiarrheal agents (episodic use allowed)~ * Antifungal agents (episodic topical use allowed)~ * Antihistamines (episodic use of loratadine, desloratadine, cetirizine allowed)~ * Cough/cold agents (episodic use allowed but preparations containing pseudoephedrine and narcotics are NOT allowed)~ * Diuretics (episodic use allowed)~* Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on item 10 (suicidal thoughts) of the Montgomery-Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.~* Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.~* Has received electroconvulsive therapy within 6 months prior to Screening.~* Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.~* Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.~* Has an alanine aminotransferase, aspartate aminotransferase or bilirubin level \>1.5 times the upper limits of normal.~* Has a serum creatinine of \>1.5 times the upper limits of normal.~* Has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication. This criterion does not include those participants with basal cell or stage I squamous cell carcinoma of the skin.~* Has clinically significant abnormal vital signs as determined by the investigator.~* Has 1 or more laboratory values outside the normal range, based on the blood or urine samples taken at Screening, that are considered by the investigator to be clinically significant.~* Has thyroid stimulating hormone value outside the normal range at Screening and is deemed clinically significant by the investigator.~* Has an abnormal electrocardiogram as determined by the central reader and confirmed as clinically significant by the investigator.~* Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.~* Has previously participated in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
- Vortioxetine 5 mg (Type: EXPERIMENTAL): Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).